Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Pharmaceutical Outsourcing Present and Future

The need for preclinical testing expertise is growing as molecular complexity increases.

Navigating the Preclinical CRO Outsourcing Process

A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.

A Closer Look at Affinity Ligands

Topic

Articles

During the first day of CPhI Worldwide in Frankfurt, Germany, a panel of experts will be discussing the evolution of CDMOs in the shifting therapeutic landscape.

Evaluating the Changing CDMO Landscape

The new services provide rapid production of antibody drug conjugates (ADCs) for best candidate selection.

MilliporeSigma Launches ADC Express Services

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Limited guidance and numerous challenges create confusion about the scope and timing of stability testing for drugs in development.

Stability Testing for Small-Molecule Clinical Trial Materials

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

As the development pipeline becomes more saturated with complex molecules and patient experience becomes more important, developers are looking to outsourcing partners to provide more specialized expertise and solutions.

The Demands of the Perfect Dose

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Establishing OEL data and ensuring appropriate engineering controls are crucial aspects of safe handling.

Best Practices in Handling HPAPIs

Jonathan Loughrey is head of screening, Cambrex Edinburgh.

An understanding-during early development-of the solid form landscape of an API can enhance product quality and manufacturing processes.

Uncovering Hidden Risks in Solid-State API Properties

New therapies, new technologies, global supply chain challenges, and political pressures draw pharma professionals to major industry event.

Market Dynamics Drive the Agenda for CPhI Worldwide

Bora Pharmaceuticals has announced it has achieved success in the latest FDA general inspection of its Zhunan facility with zero 483 observations.

Taiwanese CDMO Gains FDA Approval for Zhunan Facility

FDA issued a statement about the importance of reporting adverse events resulting from the use of compounded drugs.

Adverse Event Reporting for Compounded Drugs

The new antibody, Citryll’s CIT-013, could offer new treatment options for various human diseases including lupus, vasculitis, pulmonary fibrosis, and organ damage due to sepsis.